Yuhan Corporation’s global R&D and open innovation strategy – in which they introduce early assets from the startups, conduct preclinical & early clinical studies, then license them out to the pharmaceutical giants – is now reaping its benefits. Yuhan, which formerly led the Korean pharmaceutical industry with its sales force, has transformed itself into an […]
Here’s an update from our business partner Janssen Biotech that JNJ-6372 in combination with Lazertinib (YH25448), a novel third-generation EGFR TKI for advanced NSCLC that Yuhan Corporation out-licensed to them in November 2018, received Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA). – Article from Johnson & Johnsonhttps://lnkd.in/gFMri6P – Article from BioSpacehttps://lnkd.in/gjNTGqh
Yuhan to invest 14% of its sales in R&D this year for “Lazertinib’s Phase-3 trial & Global Open Innovation
In 2020, Yuhan Corporation is going to invest the largest amount in history for its R&D program to speed up the development of Lazertinib (YH25448) – the first-line treatment for non-small cell lung cancer (NSCLC) that has entered a phase-3 global study, and the expansion of Yuhan’s presence overseas.The company has announced to increase its […]
With 2020 just around the corner, let’s take a look back at our 2019!It has been a wonderful year for us here at Yuhan USA and may the next year be full of greater success.